Antimutagenic activity of afobazole in various regimens of treatment.

Abstract

The influence of a new 2-mercaptobenzimidazole derivative afobazole on cytogenetic effects of dioxidine and cyclophosphamide was studied by counting chromosome aberrations in bone marrow cells of C57Bl/6 mice. Afobazole (1-100 mg/kg perorally) exhibited antimutagenic activity determined by its antioxidant properties. This activity depended on the dose and treatment schedule.

• Authors: A K Zhanataev, A D Durnev, S B Seredin
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 130 Issue 11 Pg. 1077-9 (Nov 2000) ISSN: 0007-4888 [Print] United States
• PMID: 11182820 (Publication Type: Journal Article)

Chemical References

• 2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole
• Antimutagenic Agents
• Antineoplastic Agents, Alkylating
• Antioxidants
• Benzimidazoles
• Morpholines
• Oxidants
• Quinoxalines
• dioxidine
• 2-mercaptobenzimidazole
• Cyclophosphamide

Topics

• Animals
• Antimutagenic Agents (pharmacology)
• Antineoplastic Agents, Alkylating (pharmacology)
• Antioxidants (pharmacology)
• Benzimidazoles (pharmacology)
• Chromosome Aberrations
• Cyclophosphamide (pharmacology)
• Dose-Response Relationship, Drug
• Male
• Mice
• Mice, Inbred C57BL
• Morpholines (pharmacology)
• Oxidants (pharmacology)
• Quinoxalines (pharmacology)